B cell acute lymphoblastic leukemiaB-ALLALLPediatricAdultCD19CD22Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment for both pediatric and adult patients with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). Clinical trial results across multiple ...
CD19 CAR T-cells are a type of immunotherapy in which a patient's T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down...
除了上文提到的几款新型CAR-T细胞疗法外，还有多款在研的CAR-T疗法正在蓄势待发，针对多种血液肿瘤(如B细胞淋巴瘤、T细胞淋巴瘤、急性淋巴细胞白血病等)、实体瘤(如卵巢癌、肝癌等)。据ClinicalTrials.gov数据显示，截至2023年，全球免疫细胞疗法的临床研究数量超过2000项，其中，我国免疫细胞的临床研究占全球的1/3...
Despite several therapeutic advances over the past decade, multiple myeloma (MM) remains largely incurable, indicating a need for new treatment approaches. Chimeric antigen receptor (CAR) T cell therapy works by mechanisms distinct from those of other MM
CAR T cells and less T cell exhaustion. The tis-cel T cells were found to have an ongoing persistence of 20 months at the time of the report. It is known that higher leukemia burden is associated with higher CARTox, and CRS is associated with response, yet no linear relationship ...
4.Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5（177）:177ra38.5.Weber EW, Parker KR, Sotillo E, et al. Transient rest restores functionality in...
新闻来源:UCLA opens CAR T clinical trial targeting most common types of lymphoma and leukemia 2019年10月,加州大学洛杉矶分校琼森综合癌症中心启动了一项开创性的嵌合抗原受体(CAR)T细胞(CAR-T)免疫疗法临床试验。在这项临床试验中,CAR-T细胞将通过同时识别在B细胞淋巴瘤和白血病细胞表面上表达的两个靶标--- ...
时隔近两年,有关该项研究长期安全性和疗效持久性的2年随访结果,也已出炉:“Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia”并于近期发表于Journal of Hematology & Oncology(IF=23.168)(图2)。
CAR T-cell therapies have revolutionized the treatment of various B-cell malignancies [1,2,3]. Although allogeneic stem cell transplantation first demonstrated the power of adoptive T-cell transfer for combating leukemia, in AML, CAR T-cell therapy is only slowly progressing. The main challenges ...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-...